Welcome to our dedicated page for CEREVEL THERAPEU news (Ticker: CEREW), a resource for investors and traders seeking the latest updates and insights on CEREVEL THERAPEU stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CEREVEL THERAPEU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CEREVEL THERAPEU's position in the market.
Cerevel Therapeutics (Nasdaq: CERE) announced that its Chairperson and CEO, Tony Coles, M.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference. The event is scheduled for December 2, 2020, at 3:05 p.m. EST. Interested parties can access the live webcast through the investor relations section of the Cerevel website, where a replay will be available for about 90 days. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of therapies targeting conditions like schizophrenia and epilepsy.
Cerevel Therapeutics debuted on Nasdaq under the symbol CERE after a significant business combination with ARYA Sciences Acquisition Corp II, raising net proceeds of approximately $440 million. The company initiated clinical trials for its leading programs targeting schizophrenia, epilepsy, anxiety, and Parkinson's disease. Financial results for Q3 2020 revealed a net loss of $39 million, versus $36 million in Q3 2019, with cash reserves expected to fund operations into 2023. R&D expenses increased to $24 million from $17 million year-over-year.
Cerevel Therapeutics (NASDAQ:CERE) announced participation in three virtual investor conferences in November 2020. The events include:
- Guggenheim Healthcare Talks on November 16, focusing on neuro/immunology.
- Stifel 2020 Virtual Healthcare Conference on November 17, featuring a fireside chat at 10:00 a.m. EST.
- Jefferies Virtual London Healthcare Conference on November 18-19, with a chat at 10:50 a.m. EST on November 18.
Live webcasts will be available on the company's investor relations page.
Cerevel Therapeutics has initiated the first patient dosing in three Phase 3 trials for tavapadon, a treatment for Parkinson's disease. These 27-week trials, involving 1,200 patients, aim to assess the efficacy and tolerability of the drug as both a monotherapy and adjunctive therapy. Preliminary data readouts are expected in the first half of 2023. Tavapadon has shown promise in earlier trials, with a focus on receptor selectivity to reduce side effects commonly associated with similar therapies. Cerevel aims to provide a cornerstone treatment for patients at all disease stages.
Cerevel Therapeutics completed its business combination with Arya Sciences Acquisition Corp II on October 27, 2020, resulting in the formation of Cerevel Therapeutics Holdings, Inc. Common stock and warrants began trading on Nasdaq under symbols CERE and CEREW. The transaction generated $440 million in net proceeds, combining funds from Arya II's trust account and a PIPE financing. The management team, led by CEO Tony Coles, aims to address neuroscience diseases, leveraging its extensive pipeline for conditions like schizophrenia and Parkinson's disease.
